Formulation monitor
Compounded Semaglutide Injection: Evidence, Regulation, and Safety Monitor
Regulatory status monitoring for Semaglutide Injection: what category it falls into, what an approved equivalent would be, and what is and is not established about it.
Semaglutide Injection is monitored here as a injectable preparation. In regulatory terms, an FDA-approved product containing this active ingredient exists. Compounded preparations are not FDA approved, which means they have not undergone premarket review for safety, efficacy, or manufacturing quality. This page reports regulatory category and evidence status; it does not evaluate any individual product or seller.
Key findings
- Category: Injectable preparation. Approval position: An fda-approved product containing this active ingredient exists.
- Compounded preparations are not FDA approved and lack premarket review of safety, efficacy and quality.
- Where an approved product exists, FDA recommends prescribing the approved product when appropriate.
- Compounding an essentially-a-copy version of an available approved drug is restricted.
- No individual pharmacy, seller, or product is assessed on this page.
| Substance class | Injectable preparation |
|---|---|
| FDA-approved equivalent | An fda-approved product containing this active ingredient exists |
| Compounded status | Verification Pending not FDA approved; category monitored |
| Randomised evidence for this preparation | No Public Evidence Found |
| 503B bulks list position | Verification Pending |
| Current recalls naming this substance | Verification Pending |
| Monitored pharmacies listing it publicly | Verification Pending |
What regulatory category does Semaglutide Injection fall into?
Regulatory category determines almost everything that follows, and it is the question most marketing blurs. Semaglutide Injection is monitored as a injectable preparation, and an FDA-approved product containing this active ingredient exists.
Drugs made by compounders, including those made at outsourcing facilities, are not FDA-approved. They have not undergone the same premarket review as approved drugs and lack FDA review of safety, efficacy, and manufacturing quality. FDA
Section 503B restricts producing a drug product that is essentially a copy of an approved drug product. FDA Where an approved product is commercially available, that restriction is the central constraint on lawful compounding of a copy.
What is the current regulatory position on Semaglutide Injection?
Semaglutide injection shortage was resolved by FDA Declaratory Order on 21 February 2025. FDA proposed on 30 April 2026 to exclude semaglutide from the 503B bulks list, finding no clinical need for outsourcing facilities to compound it from bulk. More than 455 adverse event reports linked to compounded semaglutide had been received by FDA as of early 2025, many involving dosing errors from multidose vials.
What is specifically at issue with Semaglutide Injection?
The monitoring question for Semaglutide Injection turns on its category: injectable preparation. That category determines which regulatory pathway applies, which records exist, and which agency holds them. A injectable preparation raises different verification questions from an injectable prepared to an approved product's specification.
Because an approved equivalent exists, the restriction on compounding an essentially-a-copy product is directly engaged for Semaglutide Injection, and the relevant question becomes whether a clinical difference justifies compounding rather than dispensing the approved product.
What is established, and what is not?
The regulatory category is established and checkable. What is generally not established for a compounded preparation is its clinical performance: concentration accuracy, sterility, stability over the assigned beyond-use period, and bioavailability are properties of a specific preparation from a specific facility, not of the substance in general.
That is why this platform reports category and source rather than making product claims. A preparation is only as good as the facility that made it, and facility quality is a separate record held by state boards and FDA.
What this means
- The regulatory category of Semaglutide Injection can be stated and sourced.
- Where an approved equivalent exists, the comparison is documented.
- The distinction between approved product, compounded preparation and altered form is preserved.
What this does not mean
- That any particular compounded product is safe, effective, or accurately dosed.
- That approved-product evidence transfers to a compounded or altered preparation.
- That absence of a recall record means no quality issue has occurred.
How this substance differs from its approved counterpart
| Attribute | FDA-approved product | Compounded preparation |
|---|---|---|
| Premarket FDA review | Yes — safety, efficacy and quality | No |
| Manufacturing standard | Approved application and CGMP | 503A: state/USP standards. 503B: CGMP required |
| Concentration verification | Verified by the manufacturer | Set by the compounding facility; not independently verified here |
| Dating | Manufacturer expiry from stability testing | Pharmacy-assigned beyond-use date |
| Adverse-event reporting | Systematic post-marketing surveillance | 503B facilities report; 503A reporting is less systematic |
| Consumer verification route | FDA approval record | State licence register and, for 503B, the FDA registration list |
- This page reports regulatory category, not product quality.
- The 503B bulks list position for this substance has not been captured at this snapshot.
- Recall and enforcement records naming this substance have not been verified here.
- Regulatory position can change through rulemaking, guidance, or enforcement action.
Where does Semaglutide Injection sit on the evidence ladder?
Regulatory category is not a label — it determines what evidence exists and whether any of it transfers. These five rungs are genuinely different positions, and marketing frequently blurs adjacent ones.
Semaglutide Injection is monitored as a injectable preparation, which places it on the ladder below and fixes what can and cannot be claimed for it.
| Category | Premarket review | What the evidence position is |
|---|---|---|
| FDA-approved product | Premarket review of safety, efficacy and manufacturing quality | Randomised trial evidence in the approved indication |
| Compounded copy of an approved drug | No premarket review | Approved-product evidence does NOT transfer — the preparation is not the studied product |
| Compounded altered dosage form | No premarket review | Route-of-administration change makes bioavailability an open empirical question |
| Compounded combination | No premarket review | No approved reference product exists for the combination at all |
| Substance with no approved product | No premarket review anywhere in the supply chain | Evidence is typically preclinical or absent |
What varies between two compounded preparations of Semaglutide Injection?
This is the question that separates a regulatory answer from a practical one. Two preparations carrying the same substance name can differ in ways that materially change what a patient receives, and none of these are visible from the label alone.
- Concentration. Set by the compounding facility, not verified independently, and it can differ between fills from the same pharmacy.
- Excipients. Affect stability, tolerability and injection-site reaction, and can differ from the approved formulation.
- Beyond-use date. Assigned by the pharmacy from category rules, not derived from formal stability testing on that preparation.
- Sterility assurance. For a sterile preparation this is the highest-consequence variable and the hardest for a buyer to verify.
- Container and presentation. A multi-dose vial reintroduces a measurement step that an approved pen removes.
Each of those is a property of a specific preparation from a specific facility on a specific date — not a property of the substance. That is why this platform reports facility records rather than product claims: the facility is the variable that can actually be checked.
Sources verified for this page — 10 sources
- FDA — Information for Outsourcing Facilitieschecked 2026-07-23
- FDA — Q&A: Outsourcing Facility Registrationchecked 2026-07-23
- FDA — Registered Outsourcing Facilitieschecked 2026-07-23
- FDA — Aligning Federal and State Regulation of Compounderschecked 2026-07-23
- FDA — Outsourcing Facility Feeschecked 2026-07-23
- FDA — Compounded Drug Products That Are Essentially Copieschecked 2026-07-23
- FDA — Proposes to Exclude Semaglutide, Tirzepatide and Liraglutide from 503B Bulks List (30 Apr 2026)checked 2026-07-23
- FDA — Registration of Human Drug Compounding Outsourcing Facilities (guidance)checked 2026-07-23
- Nevada Board of Pharmacy — Notice of FDA Declaratory Orders (tirzepatide, semaglutide)checked 2026-07-23
- FDA — Outsourcing Facility Fees guidancechecked 2026-07-23
What this currently costs
Price is one of the few variables a reader can act on directly, so it is reported here rather than left to a separate page. Among the programmes this platform has verified by recomputation, the lowest regular injection rate is $145 per month on the longest commitment tier (NexLife), against higher rates on shorter terms.
Every tier behind that figure was recomputed from the published total rather than taken from the advertised per-month rate — 16 of 18 reconcile exactly, and the two that do not are published with the corrected figure on the regular injection affordability page.
Salt forms are not the same active ingredient
Some compounded products have used semaglutide salts — semaglutide sodium or semaglutide acetate — rather than semaglutide base. These are not the same active ingredient as the base form in the approved products, and FDA has stated the salt forms are not appropriate for use in compounding.
This matters for verification because it is checkable. A programme that will not state its exact salt form and concentration cannot be assessed on safety at all, and the refusal is itself the finding.
The same logic applies to any compounded peptide: the identity of what is actually in the vial is the first question, and it is answerable in writing before purchase.
| Form | What it is | Status in compounding |
|---|---|---|
| Semaglutide base | The active ingredient in the approved products | The form approved products use |
| Semaglutide sodium | A salt form, different active moiety | FDA has stated salt forms are not appropriate for compounding use |
| Semaglutide acetate | A salt form, different active moiety | FDA has stated salt forms are not appropriate for compounding use |
Related records in this section
Section hub: Medication monitors · Methodology · Status definitions · Right to respond
Frequently asked questions
What is the regulatory status of Semaglutide Injection?
Semaglutide injection shortage was resolved by FDA Declaratory Order on 21 February 2025.
Is Semaglutide Injection an approved drug, a compounded preparation, or an altered dosage form?
It is monitored here as a injectable preparation. That classification determines which regulatory pathway applies and which records exist for it.
If an approved product exists, when can Semaglutide Injection be compounded?
Section 503B restricts compounding a drug that is essentially a copy of a commercially available approved product, so the rationale must rest on a documented clinical difference.
Does this page assess any pharmacy that supplies Semaglutide Injection?
No. It reports regulatory category and position. Facility quality is a separate record held by state boards and, for outsourcing facilities, by FDA.
How would I check the facility that prepared a Semaglutide Injection product?
Check the state board licence register, and the 503B lookup for outsourcing facilities. Registration is not approval.
Sources
- FDA — Information for Outsourcing Facilities
- FDA — Q&A: Outsourcing Facility Registration
- FDA — Registered Outsourcing Facilities
- FDA — Aligning Federal and State Regulation of Compounders
- FDA — Outsourcing Facility Fees
- FDA — Compounded Drug Products That Are Essentially Copies
- FDA — Proposes to Exclude Semaglutide, Tirzepatide and Liraglutide from 503B Bulks List (30 Apr 2026)
- FDA — Registration of Human Drug Compounding Outsourcing Facilities (guidance)
- Nevada Board of Pharmacy — Notice of FDA Declaratory Orders (tirzepatide, semaglutide)
- FDA — Outsourcing Facility Fees guidance
Update history
| Date | Change |
|---|---|
| 2026-07-23 | Record published at current snapshot. |
Dates change only for substantive updates. Entities may submit a correction or response through the right-to-respond process.